Literature DB >> 15240746

Changes to peptide structure, not concentration, contribute to expansion of the lowest avidity cytotoxic T lymphocytes.

Graham R Leggatt1, Sharmal Narayan, Germain J P Fernando, Ian H Frazer.   

Abstract

The efficient in vitro expansion of antigen-specific CD8+ cytotoxic T lymphocytes (CTL) for use in adoptive immunotherapy represents an important clinical goal. Furthermore, the avidity of expanded CTL populations often correlates closely with clinical outcome. In our study, high-avidity CTL lines could be expanded ex vivo from an antigen-primed animal using low peptide concentration, and intermediate peptide concentrations favored the generation of lower avidity CTL. Further increases in peptide concentration during culture inhibited the expansion of all peptide-specific CD8+ cells. In contrast, a single amino acid variant peptide efficiently generated functional CTL populations at high or low peptide concentration, which responded to wild-type epitope with the lowest average avidity seen in this study. We propose that for some peptides, the efficient generation of low-avidity CTL responses will be favored by stimulation with altered peptide rather than high concentrations of wild-type epitope. In addition, some variant peptides designed to have improved binding to major histocompatibility complex class I may reduce rather than enhance the functional avidity for the wild-type peptide of ex vivo-expanded CTL. These observations are relevant to in vitro expansion of CTL for immunotherapy and strategies to elicit regulatory or therapeutic immunity to neo-self-antigen when central tolerance has eliminated high-avidity, cognate T cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15240746     DOI: 10.1189/jlb.0104026

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  5 in total

1.  NKT cells inhibit antigen-specific effector CD8 T cell induction to skin viral proteins.

Authors:  Stephen R Mattarollo; Michelle Yong; Christina Gosmann; Allison Choyce; Dora Chan; Graham R Leggatt; Ian H Frazer
Journal:  J Immunol       Date:  2011-07-08       Impact factor: 5.422

2.  A combination of local inflammation and central memory T cells potentiates immunotherapy in the skin.

Authors:  Salvatore Fiorenza; Tony J Kenna; Iain Comerford; Shaun McColl; Raymond J Steptoe; Graham R Leggatt; Ian H Frazer
Journal:  J Immunol       Date:  2012-11-09       Impact factor: 5.422

3.  High efficiency ex vivo cloning of antigen-specific human effector T cells.

Authors:  Michelle A Neller; Michael H-L Lai; Catherine M Lanagan; Linda E O'Connor; Antonia L Pritchard; Nathan R Martinez; Christopher W Schmidt
Journal:  PLoS One       Date:  2014-11-04       Impact factor: 3.240

4.  Methodological approach to the ex vivo expansion and detection of T. cruzi-specific T cells from chronic Chagas disease patients.

Authors:  Gonzalo R Acevedo; Silvia A Longhi; Alcinette Bunying; Nazila Sabri; Augusto Atienza; María P Zago; Radleigh Santos; Valeria A Judkowski; Clemencia Pinilla; Karina A Gómez
Journal:  PLoS One       Date:  2017-05-26       Impact factor: 3.240

Review 5.  Peptide Dose and/or Structure in Vaccines as a Determinant of T Cell Responses.

Authors:  Graham R Leggatt
Journal:  Vaccines (Basel)       Date:  2014-07-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.